Sanofi has broken ground on new EUR 400 million ($435 million) vaccine-manufacturing facility in Tuas, Singapore. The company had announced plans for the facility last year (2021).

The facility is what Sanofi is calling an “Evolutive Vaccine Facility (EVF),” which is designed around a central unit that is comprised of several digitalized modules. The EVF will be designed to allow production of three to four vaccines simultaneously and will be able to “switch” its configuration toward one vaccine process to boost supply levels and adapt to evolving public health emergencies. The facility is slated for completion by the end of 2025.

Overall, Sanofi is investing EUR 900 million ($978 million) over five years to create two new EVFs globally in Singapore and in France.

Source: Singapore Economic Development Board and Singapore Prime Minister’s Office